AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 19062107
Drug: Active counseling
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active counseling and more liberal oral fluid intake
Trial: 16827026
Drug: Hydrogen peroxide
RxNorm normalized name: Hydrogen Peroxide
DrugBank: Hydrogen peroxide (DB11091)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hydrogen peroxide exposure (33% for 30 minutes daily for five consecutive days) in Group I
Trial: 16827026
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (Group II) received no treatment
Trial: 14688827
Drug: Hepatitis G
RxNorm normalized name: Hepatitis G antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hepatitis G virus positivity in patients with Hodgkin's disease
Trial: 8683153
Drug: mAb OKT3
RxNorm normalized name: B-CELL MATURATION ANTIGEN (BCMA) CLUSTER OF DIFFERENTIATION 3 (CD3) BISPECIFIC MONOCLONAL ANTIBODY (MAB) ANTI-BCMA/ANTI-CD3 BISPECIFIC MAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mAb OKT3 infusion
Trial: 1514334
Drug: 0.5% hyperbaric
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5% hyperbaric bupivacaine combined with 0.05 mg.kg‐1 meperidine
Trial: 1514334
Drug: 0.5% hyperbaric
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5% hyperbaric bupivacaine combined with 0.1 mg.kg‐1 meperidine
Trial: 1514334
Drug: 0.5% hyperbaric
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5% hyperbaric bupivacaine combined with 0.2 mg.kg‐1 meperidine
Trial: 1514334
Drug: 0.5% hyperbaric
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5% hyperbaric bupivacaine combined with 0.3 mg.kg‐1 meperidine
Trial: 1514334
Drug: 0.5% hyperbaric
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5% hyperbaric bupivacaine combined with 0.4 mg.kg‐1 meperidine
Trial: 1514334
Drug: 0.5% hyperbaric
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5% hyperbaric bupivacaine combined with 0.5 mg.kg‐1 meperidine
Trial: 27128199
Drug: Lopinavir/ritonavir syrups
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lopinavir/ritonavir syrups
Trial: 27128199
Drug: Lopinavir/ritonavir tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lopinavir/ritonavir tablets
Trial: 23244011
Drug: Supportive psychodynamic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supportive psychodynamic psychotherapy (SPP) in addition to treatment as usual (TaU)
Trial: 21146658
Drug: Discharge antiplatelet
RxNorm normalized name: simethicone
DrugBank: Simethicone (DB09512)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Discharge antiplatelet therapy (AT)
Trial: 21146658
Drug: No discharge
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No discharge antiplatelet therapy (AT)
Trial: 21146658
Drug: Discharge monotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Discharge monotherapy
Trial: 12389066
Drug: Levosimendan (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levosimendan (2 mg i.v.)
Trial: 12389066
Drug: Levosimendan (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levosimendan (2 mg i.v.) with carvedilol (25 mg orally, twice daily for 7-9 days)
Trial: 26878875
Drug: SIT (specific
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SIT (specific immunotherapy)
Trial: 26878875
Drug: Control (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (no specific immunotherapy)
Trial: 20628237
Drug: letrozole (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: letrozole (2.5 mg/day)
Trial: 20628237
Drug: oxandrolone (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oxandrolone (2.5 mg/day)
Trial: 18381709
Drug: Pediatric antidepressant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pediatric antidepressant treatment
Trial: 16374149
Drug: 12 mL/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12 mL/kg predicted body weight tidal volume group
Trial: 16374149
Drug: 6 mL/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 mL/kg predicted body weight tidal volume group
Trial: 10894864
Drug: Gemcitabine 1,000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gemcitabine 1,000 mg/m² on days 1, 8, and 15 and cisplatin 100 mg/m² on day 2, every 4 weeks (induction chemotherapy)
Trial: 9373482
Drug: Hyaluronidase group
RxNorm normalized name: Hyaluronidase
DrugBank: Hyaluronidase (DB14740)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Hyaluronidase group (150 IU/ml hyaluronidase in anaesthetic solution)
Trial: 1606337
Drug: Piggyback (PB)
RxNorm normalized name: PB-722
DrugBank: PB-722 (DB18447)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Piggyback (PB) administration of lipids
Trial: 3661391
Drug: Sex hormone
RxNorm normalized name: Sex hormone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sex hormone levels (total and free testosterone, total and free estradiol, androstenedione, estrone) measured in cases and controls.
Trial: 29443399
Drug: Low-dose intravenous
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose intravenous soybean oil (LOW)
Trial: 29443399
Drug: Standard-dose intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-dose intravenous soybean oil (CON)
Trial: 19039919
Drug: Professional oral
RxNorm normalized name: Dentek Professional Oral Care Kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Professional oral hygiene treatment including plaque and calculus removal, root planing, motivation and instruction
Trial: 19039919
Drug: Professional oral
RxNorm normalized name: Dentek Professional Oral Care Kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Professional oral hygiene treatment
Trial: 15866609
Drug: Microdose GnRH
RxNorm normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Microdose GnRH agonist protocol
Trial: 15866609
Drug: Ganirelix acetate
RxNorm normalized name: Ganirelix Acetate
DrugBank: Ganirelix (DB06785)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ganirelix acetate (GnRH antagonist protocol)
Trial: 12766692
Drug: EX/RP with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EX/RP with medication
Trial: 12766692
Drug: Serotonergic medications
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Serotonergic medications (fluvoxamine or clomipramine)
Trial: 7579497
Drug: Mammography screening
RxNorm normalized name: SUN PROTECTANTS/SCREENS,TOPICAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mammography screening (not specified dosage or duration)
Trial: 27775810
Drug: Humanized nursing
RxNorm normalized name: Insulin Human
DrugBank: Insulin human (DB00030)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Humanized nursing combined with wet healing therapy
Trial: 27775810
Drug: Traditional method
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Traditional method of treatment for pressure ulcer
Trial: 30989175
Drug: Oral antibiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral antibiotic therapy
Trial: 24589954
Drug: Intramuscular antibiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular antibiotic therapy
Trial: 16185404
Drug: Enteral feeding
RxNorm normalized name: enteral feeding dispenser
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enteral feeding of 50 g/L glucose normal saline (GNS) 500 ml per day containing L‐Arg (400 mg/kg.day) for 4 days (Group A)
Trial: 16185404
Drug: Enteral feeding
RxNorm normalized name: enteral feeding dispenser
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enteral feeding with only 50 g/L GNS 500 ml per day for 4 days (Group C)
Trial: 11101479
Drug: Plant sterols
RxNorm normalized name: Plant Sterols/Stanol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plant sterols from rice bran oil (2.1 g/d)
Trial: 11101479
Drug: Triterpene alcohols
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triterpene alcohols from sheanut oil (2.6 g/d)
Trial: 8646143
Drug: Active cream
RxNorm normalized name: NIACINAMIDE 2 g in 100 mL / ADENOSINE 0.04 g in 100 mL TOPICAL CREAM [INCELLDERM ACTIVE CREAMEX]
DrugBank: Octisalate (DB11062)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Active cream containing aminophylline 3%, isosorbide dinitrate 0.25%, and co-dergocrine mesylate 0.05% for one week
Trial: 1550073
Drug: Calcium supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium supplementation (1000 mg Ca/d)
Trial: 28611098
Drug: Ticagrelor and
RxNorm normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ticagrelor and eptifibatide bolus with 2-hour infusion
Trial: 23250568
Drug: L-NMMA (NOS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-NMMA (NOS inhibition)
Trial: 23250568
Drug: L-NMMA +
RxNorm normalized name: L-NMMA
DrugBank: Tilarginine (DB11815)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-NMMA + ketorolac (combined intervention)
Trial: 23250568
Drug: Ketorolac +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketorolac + L-NMMA (combined intervention)
Trial: 21242235
Drug: Disease activity
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Disease activity score-driven therapy (tight control group)
Trial: 17016601
Drug: 5-FU-based adjuvant
RxNorm normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 5-FU-based adjuvant chemotherapy
Trial: 10694831
Drug: Atenolol (50-100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atenolol (50-100 mg)
Trial: 10694831
Drug: Trandolapril (2-4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trandolapril (2-4 mg)
Trial: 9219787
Drug: Combined therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined therapy with 5-ASA tablets 1.6 g/day and 5-ASA enemas 4 g/100 ml twice weekly
Trial: 9219787
Drug: Oral therapy
RxNorm normalized name: RelieVRx Virtual Reality Behavioral Therapy for Pain Relief
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral therapy with 5-ASA tablets 1.6 g/day and placebo enemas/twice weekly
Trial: 28956697
Drug: AppleMets (AMS)
RxNorm normalized name: Encora AM Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AppleMets (AMS) nutraceutical formulation containing procyanidin B2 from Annurca apples
Trial: 24991933
Drug: Nocturnal oxygen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nocturnal oxygen therapy (NOT) at 3 L/min
Trial: 24991933
Drug: Acetazolamide (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetazolamide (2 × 250 mg tablets)
Trial: 24366914
Drug: Placebo (sham-NOT/placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (sham-NOT/placebo tablets)
Trial: 18284860
Drug: Intranasal amphotericin
RxNorm normalized name: amphotericin
DrugBank: Amphotericin B (DB00681)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intranasal amphotericin B (AMB) irrigation (20 mg of AMB in 500 mL of normal saline) for 4 weeks
Trial: 18284860
Drug: Placebo (yellowish
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (yellowish dye in 500 mL of normal saline) for 4 weeks
Trial: 18284860
Drug: Intranasal amphotericin
RxNorm normalized name: amphotericin
DrugBank: Amphotericin B (DB00681)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intranasal amphotericin B (AMB) irrigation
Trial: 18284860
Drug: Intranasal amphotericin
RxNorm normalized name: amphotericin
DrugBank: Amphotericin B (DB00681)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intranasal amphotericin B (AMB) irrigation and Placebo
Trial: 9104516
Drug: bupivacaine 0.10%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: bupivacaine 0.10% and 1 mg.ml‐1 meperidine (0.10% group)
Trial: 9104516
Drug: bupivacaine 0.05%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: bupivacaine 0.05% and 1 mg.ml‐1 meperidine (0.05% group)
Trial: 9104516
Drug: 1 mg.ml‐1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg.ml‐1 meperidine (0% group)
Trial: 8026249
Drug: 1 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg/kg erythromycin
Trial: 8026249
Drug: 3 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 mg/kg erythromycin
Trial: 15191881
Drug: Erythromycin (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erythromycin (1 mg/kg)
Trial: 8026249
Drug: Erythromycin (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erythromycin (3 mg/kg)
Trial: 2784233
Drug: 1000 ppm
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1000 ppm sodium fluoride and MFP formulations
Trial: 2784233
Drug: Anticalculus agents
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anticalculus agents (HEBP and AHBP)
Trial: 31508924
Drug: HIFU hemi-ablation
RxNorm normalized name: risedronate sodium hemi-pentahydrate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HIFU hemi-ablation and concomitant short-term androgen deprivation therapy (ADT)
Trial: 28370340
Drug: P2B001 (0.6 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: P2B001 (0.6 mg pramipexole/0.75 mg rasagiline)
Trial: 28370340
Drug: P2B001 (0.3 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: P2B001 (0.3 mg pramipexole/0.75 mg rasagiline)
Trial: 28370340
Drug: Responder analysis
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Responder analysis for P2B001 (0.6/0.75 mg)
Trial: 28370340
Drug: Responder analysis
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Responder analysis for P2B001 (0.3/0.75 mg)
Trial: 17637268
Drug: ADV +
RxNorm normalized name: Black Catechu Wood/Chinese Skullcap/Chondroitin Sulfate Sodium/Dimethyl Sulfone/Glucosamine Hydrochloride/Hyaluronic Acid 66.667 MG-500 MG-500 MG-1.1 MG Oral Tablet [FOSTER&THRIVE GLUCOSAMINE CHONDROITIN ADV +MSM]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ADV + LAM (10 mg/d ADV and 100 mg/d LAM for 12 weeks, followed by 10 mg/d ADV for 36 weeks)
Trial: 17637268
Drug: Placebo +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo + LAM (placebo and 100 mg/d LAM for 12 weeks, followed by 10 mg/d ADV for 36 weeks)
Trial: 17637268
Drug: Both treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both treatment arms after 36 weeks of therapy
Trial: 9830787
Drug: High daily
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High daily dose of angiotensin-converting enzyme (ACE) inhibitors
Trial: 9830787
Drug: Low daily
RxNorm normalized name: SODIUM FLUORIDE 2.43 mg in 1 g DENTAL PASTE, DENTIFRICE [Auraglow Daily]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low daily dose of angiotensin-converting enzyme (ACE) inhibitors
Trial: 2292532
Drug: Cefpodoxime proxetil
RxNorm normalized name: Cefpodoxime Proxetil
DrugBank: Cefpodoxime (DB01416)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cefpodoxime proxetil 200 mg bd
Trial: 2292532
Drug: Co-amoxiclav 500
RxNorm normalized name: CO
DrugBank: Carbon monoxide (DB11588)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Co-amoxiclav 500 mg/125 mg tds
Trial: 27353505
Drug: blisibimod (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: blisibimod (200 mg QW)
Trial: 17044770
Drug: Tomato drink
RxNorm normalized name: Tomato
DrugBank: Tomato (DB10573)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tomato drink (250 ml)
Trial: 2060566
Drug: Doxorubicin (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxorubicin (50 mg/m2 as an iv bolus) administered at 21.00 h
Trial: 2060566
Drug: Doxorubicin (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxorubicin (50 mg/m2 as an iv bolus) administered at 09.00 h
Trial: 6340496
Drug: Hydrocortisone (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrocortisone (2 mg/kg bolus, then 0.5 mg/kg per hour for 24 hours)
Trial: 25672376
Drug: Bevacizumab and
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bevacizumab and chemotherapy
Trial: 30124724
Drug: Halobetasol propionate
RxNorm normalized name: Halobetasol Propionate
DrugBank: Ulobetasol (DB00596)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Halobetasol propionate 0.01%/tazarotene 0.045% (HP/TAZ) lotion
Trial: 20347511
Drug: Alendronate, 70
RxNorm normalized name: Alendronate, 70 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alendronate, 70 mg, administered weekly (n = 25)
Trial: 18585542
Drug: Olanzapine orally
RxNorm normalized name: Olanzapine Orally Disintegrating Tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olanzapine orally disintegrating tablet (OLZ‐ODT)
Trial: 18585542
Drug: Risperidone oral
RxNorm normalized name: risperidone Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Risperidone oral solution (RIS‐OS)
Trial: 12453852
Drug: vinorelbine-cisplatin (NP;
FDA approved: no
EMA approved: no
PMDA approved: no
Description: vinorelbine-cisplatin (NP; vinorelbine 30 mg/m(2) on days 1, 8 and 15 with cisplatin 80 mg/m(2) on day 1)
Trial: 12453852
Drug: vinorelbine-ifosfamide-cisplatin (NIP;
FDA approved: no
EMA approved: no
PMDA approved: no
Description: vinorelbine-ifosfamide-cisplatin (NIP; vinorelbine 25 mg/m(2) on days 1 and 8, ifosfamide 3 g/m(2) on day 1 and cisplatin 75 mg/m(2) on day 1)
Trial: 6725040
Drug: Radiosensitizing drug
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Radiosensitizing drug in radiotherapy
Trial: 29790614
Drug: Probiotic treatment
RxNorm normalized name: Rezyst Probiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotic treatment (Lactobacillus rhamnosus and Enterococcus faecium)
Trial: 24032706
Drug: Low-dose intravenous
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose intravenous heparin infusion (8 U/kg/hr progressing to 10 U/kg/hr over 36 hours) starting 12 hours after surgery until Day 14
Trial: 24032706
Drug: Conventional subcutaneous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional subcutaneous heparin twice daily as deep vein thrombosis prophylaxis
Trial: 20205099
Drug: Levothyroxine (LT(4))
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levothyroxine (LT(4)) treatment for one year
Trial: 20205099
Drug: Iodine treatment
RxNorm normalized name: Iodine
DrugBank: Iodine (DB05382)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Iodine treatment only (Control)
Trial: 14711190
Drug: 20 mg/day
RxNorm normalized name: futibatinib 20 mg/day (4 mg x 5) ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg/day atorvastatin for 3 months
Trial: 14711190
Drug: 80 mg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 80 mg/day atorvastatin for 3 months
Trial: 10781354
Drug: Thrombolytic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thrombolytic therapy in community hospitals (group A)
Trial: 10781354
Drug: Thrombolytic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thrombolytic therapy during transportation to angioplasty (group B)
Trial: 10781354
Drug: Immediate transportation
RxNorm normalized name: transforming growth factor beta 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate transportation for primary angioplasty without pre-treatment with thrombolysis (group C)
Trial: 2056455
Drug: 0.12% chlorhexidine
RxNorm normalized name: CHLORHEXIDINE GLUCONATE 1.2 [iU] in 1 mL BUCCAL MOUTHWASH [0.12% Chlorhexidine Gluconate Oral Rinse]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.12% chlorhexidine gluconate rinsing (15 ml b.i.d.)
Trial: 2056455
Drug: Tap water
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tap water rinsing (15 ml b.i.d.)
Trial: 6352046
Drug: Timed-release dihydroergotamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Timed-release dihydroergotamine preparation 10 mg/per os/day
Trial: 30992295
Drug: 2-week antibiotic
RxNorm normalized name: lacosamide
DrugBank: Lacosamide (DB06218)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 2-week antibiotic therapy
Trial: 30992295
Drug: 4-week antibiotic
RxNorm normalized name: milnacipran
DrugBank: Milnacipran (DB04896)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 4-week antibiotic therapy
Trial: 21159841
Drug: Denosumab 60
RxNorm normalized name: denosumab 60 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Denosumab 60 mg sc every 6 months
Trial: 27270237
Drug: Zoledronic Acid
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Zoledronic Acid 5 mg iv once
Trial: 24570297
Drug: Medication Monitoring
RxNorm normalized name: iodine
DrugBank: Iodine (DB05382)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Medication Monitoring and Optimization (MeMO) intervention, comprising continuous monitoring and tailored counseling sessions, N = 495
Trial: 22050030
Drug: Methamphetamine (0,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methamphetamine (0, 12, 50 mg/70 kg)
Trial: 22050030
Drug: d-amphetamine (0,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: d-amphetamine (0, 12, 50 mg/70 kg)
Trial: 11958805
Drug: Alcohol (0.7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alcohol (0.7 g/kg body mass) given 1 h after exercise
Trial: 11958805
Drug: Alcohol-free solution
DrugBank: Benzalkonium (DB11105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Alcohol-free solution administered 1 h after exercise
Trial: 16256705
Drug: R(+)‐ and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: R(+)‐ and S(‐)‐thioctic acid (TA) enantiomers administered orally and intravenously at a single dose of 200 mg rac‐TA.
Trial: 2495910
Drug: Intravenous rtPA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous rtPA (total dose, 100 mg over 3 h)
Trial: 699627
Drug: Diflunisal (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diflunisal (500 mg) twice daily